Kristina Jankovic, MD· @JankovicK · X·· 1 天前评分70
正文 · 机器翻译
#ESMO26 | postMONARCH – 最终 OS
Abemaciclib + fulvestrant 🆚 placebo + fulvestrant：既往接受过 CDK4/6i 治疗的 HR+/HER2− 晚期 #BreastCancer：
🔹 mOS 32.1 🆚 24.6 个月（HR 0.80；p=0.11）——数值上有获益，但无统计学显著性。
同步发表于 @Annals_Oncology 👇
🔗 http://annalsofoncology.org/article/S0923-7534%2826%2908075-0/
#bcsm @myESMO @OncoAlert
38 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
1RO按 Rapid oral 1: Breast cancer, advanced stage 对上
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.org来源：Kristina Jankovic, MD · x.com